Anti-CD4 monoclonal antibody (Immunotech) |
|
Phase Ⅱ |
Immunotech |
HIV infection |
Details
|
F-105 |
F-105 |
Phase Ⅰ |
Centocor |
HIV infection |
Details
|
EC-18 |
EC-18 |
Phase Ⅱ |
Enzychem Lifesciences |
Neutropenia |
Details
|
PRO-542 |
PRO-542 |
Phase Ⅱ |
Columbia University, Progenics Pharmaceutical |
HIV infection |
Details
|
GEN-009 |
GEN-009 |
Phase Ⅱ |
Genocea Biosciences |
Solid tumours |
Details
|
ITV 1(Nonindustrial source) |
ITV-1 |
Phase Ⅲ |
Nonindustrial source, Immunotech Laboratories, Synexa Life Sciences |
HIV infection |
Details
|
Cedelizumab |
|
Phase Ⅱ |
Ortho-McNeil |
Autoimmune diseases, Transplant rejection |
Details
|
TMB-365 |
TMB-365 |
Phase Ⅰ |
TaiMed Biologics |
HIV infection |
Details
|
802-2 |
802-2; Anti-CD4 802-2; cnscqic-cyclic |
Phase Ⅱ |
Thomas Jefferson University, Synthetic Biologics |
Graft versus host disease |
Details
|
Radiolabeled anti-CD4 monoclonal antibody fragment (Biotectid) |
EP-1645 |
Phase Ⅱ |
BIOTECTID |
Carotid stenosis, Rheumatoid arthritis (RA) |
Details
|
Zanolimumab |
HuMaxCD4; MDX-CD4; MDX-016 |
Phase Ⅲ |
Genmab, Emergent BioSolutions |
Cutaneous T cell lymphoma (CTCL), Rheumatoid arthritis (RA) |
Details
|
Anti-CD4 monoclonal antibody 4162W94 |
|
Phase Ⅱ |
GlaxoSmithKline |
Rheumatoid arthritis (RA) |
Details
|
Clenoliximab |
IDEC 151; SB-217969,SB 217969 |
Phase Ⅱ |
Biogen Idec |
Psoriasis, Rheumatoid arthritis (RA), Asthma |
Details
|
HIV-1 peptide vaccine (microparticulate/monovalent, UBI) |
|
Phase Ⅰ |
United Biomedical |
HIV infection |
Details
|
RAP-102 |
RAP-102; KLH-RAP 101,RAP 102,RAP102 |
Phase Ⅰ |
RAPID Pharmaceuticals |
HIV infection, Multiple sclerosis (MS) |
Details
|
VRC-HIVMAB091-00-AB |
N6LS; VRC-HIVMAB091-00-AB; Z258‐N6LS |
Phase Ⅰ |
National Institute of Allergy and Infectious Diseases |
HIV infection |
Details
|
CD4 CAR T cell therapy (iCell Gene Therapeutics) |
|
Phase Ⅰ |
iCell Gene Therapeutics |
Multiple myeloma (MM) |
Details
|
IT-1208 (Kyowa Hakko Kirin) |
IT-1208 |
Phase Ⅰ |
Kyowa Hakko Kirin, Ono Pharmaceutical |
Solid tumours |
Details
|
VRC-HIVAAV070-00-GT |
AAV8-VRC07 |
Phase Ⅰ |
National Institute of Allergy and Infectious Diseases |
HIV infection |
Details
|
CEL-1000 |
CEL-1000 |
Preclinical |
CEL-SCI |
Malaria, West nile virus infection, Smallpox infection, HBV infection, Venezuelan equine encephalitis virus infection, Herpes simplex virus (HSV) infection |
Details
|
T-allo-10 |
T-allo-10 |
Phase Ⅰ |
Stanford University |
Graft versus host disease |
Details
|
CD4-directed chimeric antigen receptor engineered T-cells (Stony Brook University) |
CD4CAR |
Phase Ⅰ |
Stony Brook University School of Medicine, University of Louisville, iCell Gene Therapeutics |
Leukemia, T cell lymphoma |
Details
|
HuB-F5 antibody (Diaclone) |
|
Phase Not Specified |
Tepnel Pharma |
Rheumatoid arthritis (RA) |
Details
|
CALRLong36 peptide (Herlev Hospital) |
|
Phase Ⅰ |
Herlev Hospital |
Myeloproliferative neoplasms |
Details
|
BG-8962 |
BG-8962 |
Phase Ⅰ |
National Institute of Allergy and Infectious Diseases |
HIV infection |
Details
|
Anti-CD4 idiotype vaccine (Nonindustrial source) |
|
Phase Ⅱ |
Nonindustrial source |
HIV infection |
Details
|
Priliximab |
CEN-000029; cMT-412; MT-412 |
Phase Ⅱ |
Centocor |
Rejection in heart transplantation, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Crohn's disease, Non-Hodgkin's lymphoma (NHL) |
Details
|
3BNC-117 |
3BNC-117 |
Phase Ⅱ |
Rockefeller University |
HIV infection |
Details
|
Anti-CD4 monoclonal antibody (Tolerx) |
TRX-1 (Tolerx); MTRX-1011A; RG-7424 |
Phase Ⅰ |
University of Oxford, Genentech, Tolerx |
Cutaneous lupus erythematosus, Autoimmune diseases, Rheumatoid arthritis (RA) |
Details
|
RB-0003 |
RB-0003 |
Phase Ⅱ |
BioNTech, TRON |
Melanoma |
Details
|
LCAR-T2C CAR-T cell therapy (Nanjing Medical University) |
|
Phase Ⅰ |
The First Affiliated Hospital with Nanjing Medical University |
T cell lymphoma |
Details
|
Tregalizumab |
BT-061; hB-F5 |
Phase Ⅱ |
Biotest, Abbvie, Boehringer Ingelheim |
Plaque psoriasis, Rheumatoid arthritis (RA) |
Details
|
R-95288 |
R-95288; SA-1080; S-1443; RKS-1443,R 95288; SA 1080; S 1443; RKS 1443,R95288; SA1080; S1443; RKS1443 |
Phase Ⅰ |
Daiichi Sankyo |
HIV infection |
Details
|
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) |
CAR-C34ZFN |
Phase Ⅰ |
University of Pennsylvania |
HIV infection |
Details
|
VRC-01-LS |
VRC-HIVMAB-080-00-AB; VRC-01-LS |
Phase Ⅰ |
National Institute of Allergy and Infectious Diseases, Xencor |
HIV infection |
Details
|
RBC-CD4 (Sheffield Medical Technologies) |
|
Phase Ⅱ |
Sheffield Pharmaceuticals |
HIV infection |
Details
|
Keliximab |
SB-210396; IDEC-CE9.1,SB 210396 |
Phase Ⅲ |
Biogen, GlaxoSmithKline |
Rheumatoid arthritis (RA), Asthma |
Details
|
VRC-07-523 |
VRC-07-523; VRC-07-523-L S; VRC-HIVMAB-075 -00-AB; VRC-HIVMAB075-00-AB |
Phase Ⅰ |
National Institutes of Health |
HIV infection |
Details
|
Anti-CD3 anti-CD20 bispecific antibody (Genmab) |
GEN-3013 |
Phase Ⅱ |
Genmab |
hematological malignancies |
Details
|
UB-421 |
dB4; mAb-B4; UB-421 |
Phase Ⅲ |
United Biomedical, United BioPharma |
HIV infection |
Details
|
HIV vaccines polytope (Bavarian Nordic/VaxOnco) |
EP-1232; EP-1233; MVA-BN32; MVA-mBN32 |
Phase Ⅱ |
Bavarian Nordic, KAEL-GemVax |
HIV infection |
Details
|
AVR-01 |
AVR-01 |
Phase Ⅰ |
AVROBIO |
Acute myeloid Leukemia (AML) |
Details
|
3-BNC-117-LS (Rockefeller University) |
3-BNC-117-LS |
Phase Ⅰ |
Rockefeller University |
HIV infection |
Details
|
MVA-EL |
MVA-EBNA1/LMP2 |
Phase Ⅱ |
Cancer Research UK, Chinese University of Hong Kong (CUHK) |
Nasopharyngeal cancer |
Details
|
T cell gene therapy (Cell Genesys) |
|
Phase Ⅱ |
Cell Genesys |
HIV infection, Colorectal cancer |
Details
|